Meeting
2023 ASCO Genitourinary Cancers Symposium
READY: Real-world data from an Italian compassionate use program of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC).
Authors
Lorenzo Antonuzzo
Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
Lorenzo Antonuzzo , Marco Maruzzo , Ugo De Giorgi , Daniele Santini , Rosa Tambaro , Sebastiano Buti , Francesco Carrozza , Fabio Calabrò , Giuseppe Di Lorenzo , Giuseppe Fornarini , Roberto Iacovelli , Daniela Cullurà , Carlo Messina , Claudia Masi , Angelo Ciccia , Gennaro Fazzi , Filippo Venturini , Raffaele Colasanto , Andrea Necchi , Sergio Bracarda
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Clinical Trial Registration Number
NCT02603432
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 469)
DOI
10.1200/JCO.2023.41.6_suppl.469
Abstract #
469
Poster Bd #
H10
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Subgroup analyses from READY: Real-world data from an Italian compassionate use program (CUP) of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC).
First Author: Sergio Bracarda
Poster
2023 ASCO Genitourinary Cancers Symposium
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy.
First Author: Srikala S. Sridhar
Poster
2021 ASCO Annual Meeting
Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100.
First Author: Petros Grivas
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world (rw) treatment patterns, sequencing, and outcomes in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) receiving avelumab first-line maintenance (1LM) in the US.
First Author: Helen H. Moon